From bullybears@msn.com Fri Jul 17 04:53:31 1998
Return-Path: <bullybears@msn.com>
Delivered-To: bguenter@hal.qcc.sk.ca
Received: (qmail 26418 invoked by alias); 17 Jul 1998 04:53:30 -0000
Received: (qmail 26411 invoked from network); 17 Jul 1998 04:53:29 -0000
Received: from linus.vsource.com (qmailr@198.169.201.2)
  by hal.qcc.sk.ca with SMTP; 17 Jul 1998 04:53:29 -0000
Received: (qmail 3034 invoked by uid 559); 17 Jul 1998 04:37:19 -0000
Delivered-To: bguenter@gemprint.com
Received: (qmail 3019 invoked from network); 17 Jul 1998 04:32:31 -0000
Received: from oliv.sbnet.ru (193.233.65.2)
  by www.gemprint.com with SMTP; 17 Jul 1998 04:32:31 -0000
Received: from 193.233.65.2 (2Cust15.tnt1.mia1.da.uu.net [153.35.29.15]) by oliv.sbnet.ru (8.7.6/8.7.3) with SMTP id HAA12364; Fri, 17 Jul 1998 07:18:06 GMT
From: bullybears@msn.com
Date: Thu, 16 Jul 98 22:06:05 EST
To: boundry@cit.ics.saitama-u.ac.jp
Subject: Cancer Treatment Breakthrough!!!
Message-ID: <199807061134.HAA13720@cit.ics.saitama-u.ac.jp>
Reply-To: bulltrader@cit.ics.saitama-u.ac.jp

DRAMATICALLY EFFECTIVE CANCER

TREATMENT IN FINAL DEVELOPMENT


Now you can participate in the multi-billion
dollar cancer treatment industry by owning
stock in this company before the "Wall Street
Analysts" discover it. The company is in
the final stages of researching and
developing this new drug to help cure soft
tissue cancers of the liver, breast and lungs.

This company is led by a very distinguished
team of Cancer Research Specialists who have
studied this disease for the last two decades.
The company holds the worldwide manufacturing
and marketing rights (except for the former
Soviet Union) for this drug.

The company is called :

NuOncology Labs Inc.

Trading Symbol: NLAB

Trades:   OTC  BB

Trials are now being conducted on over 200
human cancer patients with this new drug and
some very important announcements are
expected to come from NuOncology over the
next few weeks.

To have complete investor information sent to
you please call:

604.720.4153

We profile companies at the time they initially
go public - before they have been discovered
by 'The Street' and financial media and have
by that time already doubled or tripled in price.
By requesting additional information on
NuOncology Labs, Inc., you are also requesting
a subscription to our newsletter that profiles
emerging new companies. There is no obligation
and absolutely no cost to you. You may
unsubscribe at any time.




